Tip of the Iceberg? Country- and Company-Level Analysis of Drug Company Payments for Research and Development in Europe.

ABSTRACT:

Background

Creating new therapies often involves drug companies paying healthcare professionals and institutions for research and development (R&D) activities, including clinical trials. However, industry sponsorship can create conflicts of interest (COIs). We analysed approaches to drug company R&D payment disclosure in European countries and the distribution of R&D payments at the country and company level.

Methods

Using documentary sources and a stakeholder survey we identified country- regulatory approaches to R&D payment disclosure. We reviewed company-level descriptions of disclosure practices in the United Kingdom, a country with a major role in Europe's R&D. We obtained country-level R&D payment data from industry trade groups and public authorities and company-level

SUBMITTER: Ozieranski P 

PROVIDER: S-EPMC10105170 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature